Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.

•NSCLC patients have a clinically meaningful risk of HBV reactivation during EGFR TKI treatment.•No independent risk factors were identified for HBV reactivation during EGFR TKI treatment.•HBV screening and monitoring liver function are recommended for NSCLC patients before and during EGFR TKI treatment.